New hope for bile duct cancer: targeted combo targets hard-to-treat gene mutation
NCT ID NCT07282262
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a precision medicine approach for people with advanced biliary tract cancer that has a specific IDH1 gene mutation and has stopped responding to standard chemotherapy. About 300 participants will receive a combination of ivosidenib (a targeted pill) plus either lenvatinib or an immunotherapy drug. The goal is to see if this combination can shrink tumors or slow cancer growth.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Peking Union Medical College Hospital Outpatient Department
RECRUITINGBeijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart drug home in on Hard-to-Treat cancers?
- Can a new immunotherapy combo shrink Hard-to-Treat tumors?
- Can two targeted drugs boost chemo against a rare Bile-Duct cancer?
- New drug cocktail aims to outperform standard immunotherapy in bile duct cancer
- Liver cancer registry aims to uncover new biomarkers from thousands of patients
- Triple-Drug cocktail targets Hard-to-Treat biliary cancers